Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly FCF Margin of 88028.57% in Q4 2025, down 198.97% on a QoQ basis from 29444.0% in Q3 2025, and down 8262474.0% YoY from N/an in Q4 2024.
Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported FCF Margin for 5 consecutive years, with 88028.57% the latest figure, recorded in Q4 2025.
- FCF Margin for Q4 2025 came in at 88028.57%, down 8262474.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 7275.13% (down 255876.0% YoY), and the FY2025 annual result was 7280.15%, down 256379.0% from the prior year.
- FCF Margin for Q4 2025 stood at 88028.57%, down from 29444.0% in the prior quarter.
- The five-year high for FCF Margin was 1596.76% in Q2 2022, with the low at 110836.36% in Q4 2022.
- A 5-year average of 20091.16% and a median of 4250.82% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 10703968 bps in 2022 and jumped 9753431 bps in 2023, its largest moves.
- Lyra Therapeutics' FCF Margin stood at 3796.68% in 2021, then sank by 2819 bps to 110836.36% in 2022, then surged by 88 bps to 13302.05% in 2023, then soared by 59 bps to 5403.83% in 2024, then sank by 1529 bps to 88028.57% in 2025.
- The last three FCF Margin figures came in at 88028.57% (Q4 2025), 29444.0% (Q3 2025), and 3601.09% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 70.82% |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -87,357.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -88,028.57% |
| Sep 30, 2025 | -29,444.00% |
| Jun 30, 2025 | -3,601.09% |
| Mar 31, 2025 | -4,831.69% |
| Dec 31, 2024 | -5,403.83% |
| Sep 30, 2024 | -9,515.38% |
| Jun 30, 2024 | -2,992.64% |
| Mar 31, 2024 | -4,624.81% |
| Dec 31, 2023 | -13,302.05% |
| Sep 30, 2023 | -2,620.96% |
| Jun 30, 2023 | -3,133.84% |
| Mar 31, 2023 | -3,876.83% |
| Dec 31, 2022 | -110,836.36% |
| Sep 30, 2022 | -3,057.38% |
| Jun 30, 2022 | -1,596.76% |
| Mar 31, 2022 | -2,563.68% |
| Dec 31, 2021 | -3,796.68% |
| Sep 30, 2021 | -68,414.29% |